Extended Validation of Donor-derived Cell-free DNA in Kidney Transplant Recipients

Authors
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2026
This is a multinational, multi-center, observational cohort study. Kidney allograft rejection is poorly detected by standard-of-care biomarkers. Although dd-cfDNA has been associated with improved rejection detection when added to standard-of-care biomarkers and clinical parameters, little is known about its performance across Banff 2022 rejection phenotypes and injury patterns, in various clinical scenarios and populations, and when measured repeatedly over time.
Epistemonikos ID: 7ae33475ef9a069c0d32400a0f6061bf28f2e41c
First added on: Sep 05, 2026